Core Points - The company, Harbin Sanlian Pharmaceutical Co., Ltd., has released its 2025 semi-annual report, which includes important financial and operational information [1][15]. - The board of directors and the supervisory board have both approved the semi-annual report and related documents, confirming that the information disclosed is true, accurate, and complete [24][26]. Group 1: Board Meeting - All directors attended the board meeting that reviewed the semi-annual report [2][11]. - The meeting was held on August 25, 2025, and all 9 directors participated in the voting process [10][12]. - The board approved the proposal regarding the 2025 semi-annual report with unanimous support [13][14]. Group 2: Supervisory Board Meeting - The supervisory board meeting was also held on August 25, 2025, with all 3 supervisors present [21][22]. - The supervisory board confirmed that the procedures for preparing and reviewing the semi-annual report complied with relevant laws and regulations [24]. - The board approved the proposal regarding the use of raised funds, stating that there were no violations or misuses of the funds [26].

Group 1 - The second meeting of the supervisory board of Xinjiang Li New Energy Co., Ltd. was held on March 15, 2025, with all three supervisors present [1] - The supervisory board approved the annual work report for 2024, which summarizes the board's responsibilities and activities [2] - The supervisory board also approved the 2024 annual report and its summary, confirming that the content is true, accurate, and complete [2][3] Group 2 - The supervisory board approved the internal control evaluation report for 2024, which reflects the company's internal control system's construction and operation [3] - The financial report for 2024 was audited by Zhongxinghua Accounting Firm, and the board approved it [4] - The company expects a revenue of no less than 1 billion yuan for 2025, representing a year-on-year growth of 3.02%, and a profit of no less than 100 million yuan, indicating a growth of 29.73% [4] Group 3 - The supervisory board approved the profit distribution plan for 2024, which complies with relevant regulations [5] - The board discussed the expected related party transactions for 2025, but due to a lack of quorum, no resolution was made [5] - The supervisory board approved a financing limit of up to 20 billion yuan for 2025 for the company and its subsidiaries [6] Group 4 - The supervisory board reviewed the special report on the use of raised funds, confirming compliance with regulations and no misuse of funds [6] - The board approved the two-year audit report, confirming that the financial statements for 2022 and 2023 were prepared in accordance with accounting standards [7][8] - The supervisory board approved the application for issuing REITs with a total scale not exceeding 1.5 billion yuan [9]